Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$351 Mln
P/E Ratio
--
P/B Ratio
43.84
Industry P/E
--
Debt to Equity
9.15
ROE
-1.89 %
ROCE
-31.13 %
Div. Yield
0 %
Book Value
0.28
EPS
-0.94
CFO
$-127.78 Mln
EBITDA
$-126.04 Mln
Net Profit
$-201.16 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Neuropace Inc (NPCE)
| -5.81 | -9.45 | -11.95 | -24.61 | 7.43 | -- | -- |
|
BSE Sensex*
| 1.83 | 3.61 | 5.06 | 9.02 | 11.22 | 21.07 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Neuropace Inc (NPCE)
| 8.46 | 591.95 | -85.22 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 14.96 | 10,289.47 | 14.52 | 12.69 | |
| 69.39 | 9,766.86 | 94.68 | 2.52 | |
| 270.64 | 10,728.92 | 770.42 | 1.2 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant... focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. Address: 455 North Bernardo Avenue, Mountain View, CA, United States, 94043 Read more
Chief Medical Officer
Dr. Martha J. Morrell
Chief Medical Officer
Dr. Martha J. Morrell
Headquarters
Mountain View, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Neuropace Inc (NPCE) stood at $ 95 Mln as on 31-Dec-24
The share price of Neuropace Inc (NPCE) is $10.54 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Neuropace Inc (NPCE) has given a return of 7.43% in the last 3 years.
Neuropace Inc (NPCE) has a market capitalisation of $ 351 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Neuropace Inc (NPCE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Neuropace Inc (NPCE) and enter the required number of quantities and click on buy to purchase the shares of Neuropace Inc (NPCE).
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. Address: 455 North Bernardo Avenue, Mountain View, CA, United States, 94043
The CEO & director of Dr. Martha J. Morrell. is Neuropace Inc (NPCE), and CFO & Sr. VP is Dr. Martha J. Morrell.
There is no promoter pledging in Neuropace Inc (NPCE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,070
|
|
|
1,049
|
|
|
978
|
| Neuropace Inc (NPCE) | Ratios |
|---|---|
|
Return on equity(%)
|
-189.35
|
|
Operating margin(%)
|
-22.96
|
|
Net Margin(%)
|
-33.97
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Neuropace Inc (NPCE) was $0 Mln.
$-0.25
(
